Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 14/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 14/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 2/20 | 0.48 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970433 | 0.89 | RBP4 (0.53) | MAPK1EP300CREBBPBRD4DPP4 | |
| SCHEMBL1006514 | 0.87 | DPP4 (0.50) | MAPK1EP300CREBBPBRD4DPP4 | |
| SCHEMBL16219036 | 0.85 | DPP4 (0.52) | MAPK1EP300CREBBPBRD4DPP4 | |
| SCHEMBL1009435 | 0.83 | DPP4 (0.46) | MAPK1EP300CREBBPBRD4DPP4 | |
| SCHEMBL31496063 | 0.81 | MAPK1 (0.56) | MAPK1EP300CREBBPBRD4LMNA | |
| SCHEMBL14970405 | 0.79 | CREBBP (0.59) | MAPK1EP300CREBBPBRD4LMNA | |
| SCHEMBL21255655 | 0.78 | MAPK1 (0.56) | MAPK1EP300CREBBPBRD4LMNA | |
| SCHEMBL17795280 | 0.78 | MAPK1 (0.60) | MAPK1EP300CREBBPBRD4LMNA | |
| SCHEMBL17785625 | 0.78 | MAPK1 (0.56) | MAPK1EP300CREBBPBRD4LMNA | |
| SCHEMBL2969795 | 0.77 | MAPK1 (0.77) | MAPK1EP300CREBBPBRD4RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| WO-2013074388-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | MAPK1 2413/4885EP300 2331/4885CREBBP 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.